According to Legacy Bioscience, peptides are naturally present in the human body and help regulate biological functions including healing, digestion, and cell signaling
However, its important to note that 24 weeks, while substantial for clinical trials, represents a relatively limited timeframe for assessing lifetime exposure safety
Development status, where Cagrilintide is in 2026 Cagrilintide is in Phase 3 clinical trials as part of the CagriSema combination
If one causes intolerable side effects, trying the other is reasonable
Contraindications and clinical precautions include: Medullary thyroid carcinoma (MTC): Cagrilintide is contraindicated in individuals with a personal or family history of MTC due to its structural similarity to calcitonin, which may theoretically influence C-cell activity